Revolution Medicines, Inc. Warrant
RVMDW
About: Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Employees: 700
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
597% more capital invested
Capital invested by funds: $316K [Q1] → $2.2M (+$1.89M) [Q2]
69.03% more ownership
Funds ownership: 4.14% [Q1] → 73.17% (+69.03%) [Q2]
4% less funds holding
Funds holding: 24 [Q1] → 23 (-1) [Q2]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Financial journalist opinion
We haven’t received any recent news articles for RVMDW